metastaticmicrosatelliteinstabilityhigh

PURPOSEKEYNOTE-164 (NCT02460198) evaluated the antitumor activity of pembrolizumab in previously treated, metastatic, microsatellite instability–high/mismatch

由 HJ Lenz 著作 · 2022 · 被引用 313 次 — First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate ...

由 K Li 著作 · 2020 · 被引用 348 次 — The patients with high microsatellite instability (MSI-H)/mismatch repair deficient (dMMR) tumors recently have been reported that can ...

Describes cancer cells that have a high number of mutations (changes) within microsatellites. For example, microsatellite testing that shows mutations in ...

2023年3月6日 — Metastasis (30) ... Immunotherapy increases the body's ability to identify and attack these cells, and cancers that have high microsatellite ...

由 S Han 著作 · 2022 · 被引用 3 次 — Microsatellite-instability-high (MSI-H) cancers are a unique class of tumors that may arise from somatic inactivating mutations or epigenetic ...

由 T Buchler 著作 · 2022 · 被引用 17 次 — Mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal tumours are identified in approximately 15% of CRC patients.

由 T André 著作 · 2020 · 被引用 1780 次 — In this phase 3, open-label trial, 307 patients with metastatic MSI-H–dMMR colorectal cancer who had not previously received treatment were ...

由 LA Diaz 著作 · 2022 · 被引用 310 次 — Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): ...